Phase 1 Type 2 Diabetes Trial, Recruiting NCT07588503 Sponsor: Dr. B. Catharine. Craven Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 1 Type 2 Diabetes Trial, Recruiting

NCT07588503
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 75 years old
  • People of any gender (male or female)
  • People who have had a spinal cord injury for more than one year
  • People who have been diagnosed with a spinal cord injury at a specific level of the spine (between the 5th cervical and 10th thoracic vertebrae), whether caused by an accident or a medical condition, and across a range of injury severities (confirm with trial site for exact classification)
  • People who have three or more risk factors related to heart and metabolic health (confirm with trial site for specific risk factors)

Who may not be able to join:

  • People with a past or current history of blood clots in the veins (such as deep vein thrombosis or pulmonary embolism)
  • People with a pressure sore or skin wound on the pelvis, mid-to-upper thigh, or foot
  • People currently managing a broken bone in a leg
  • People with any history of a stroke caused by a blood clot
  • People who have had a heart attack
  • People with high blood pressure that is currently not being treated
  • People with a language, psychiatric, thinking, or communication difficulty (such as a brain injury) that could affect their ability to freely agree to join, follow the study instructions, or operate the study device
  • People with a current alcohol or illicit drug use disorder
  • People currently taking blood-thinning medication
  • People who frequently experience episodes of a sudden dangerous rise in blood pressure (autonomic dysreflexia) that does not respond to treatment, such as 3–5 times per week
  • People who have had an unresolved deep vein blood clot in the past six months
  • People with severe muscle stiffness that prevents the leg movement needed for cycling
  • People who have an active implanted medical device, such as a pacemaker or an intrathecal baclofen pump
  • People who are unable to give informed consent to participate in the study
  • People with serious ongoing medical conditions, such as skin infections, breathing infections, or pressure sores
  • People with an unstable spine or unhealed broken bones in the limbs or pelvis
  • People with active abnormal bone growth (heterotopic ossification) that limits movement in the lower limbs

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 4165973422

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Dr. B. Catharine. Craven
Registry
ClinicalTrials.gov
Start date
15 June 2026
Est. completion
1 January 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Participant Retention; Safety - Skin Checks; Safety - Adverse Event Report; Recruitment Rate; Change in CMD Risk Profile - Lipid Profile; Participant Perspectives and Experience; Safety - Heart Rate; Safety - Blood Pressure; Safety - Oxygen Saturation; Safety - Rating of Perceived Exertion and Discomfort.; Change in CMD Risk Profile - C-Reactive Protein; Change in CMD Risk Profile - Hemoglobin A1c; Change in CMD Risk Profile - Fasted Plasma Glucose; Change in CMD Risk Profile - Waist Circumference; Change in CMD Risk Profile - Body Mass Index

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov